Chidamide, an HDAC1 inhibitor, prohibits TGFβ‐induced SMAD2 phosphorylation and attenuation of TGFβ‐induced loss of E‐cadherin expression, leading to the inhibition of migration in lung cancer cells [245]. Here, SMAD2 is linked to lung carcinoma.